Floatz logo

IM19 CAR-T cells

Lymphoma, Mantle-Cell

Beijing Immunochina Medical Science & Technology Co., Ltd.Cell therapyPhase 1/2Active
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
89/ 100

Competitive context

172 Active assets in the Lymphoma, Mantle-Cell cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
Ruijin Hospital
Phase 4BBB
CIS-DIAMMINEDICHLOROPLATINUM II
National Cancer Institute (NCI)
Phase 4BBB
Bendamustine
Czech Lymphoma Study Group
Phase 2BBB
VINCRISTINE SULFATE
M.D. Anderson Cancer Center
Phase 2BBB
Irinotecan
University of Michigan Rogel Cancer Center
Phase 2BBB

View all 50 →

Same molecule, other indications

IM19 CAR-T cells is also rated in:

non-Hodgkin lymphomaDormant
CC
Indicative ·
47 / 100
View asset →
lymphoproliferative syndromeDormant
CC
Indicative ·
47 / 100
View asset →
leukemiaDormant
CC
Indicative ·
46 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →